Hilversum, Netherlands — October 31, 2024 — NEC Bio (NB), a leading artificial intelligence (AI) company in drug development field, today announced its participation in the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, from November 6 to 10, 2024. NEC Bio uses its cutting-edge AI technology to develop vaccines for oncology and several infectious diseases. The technology is presented as a poster in the conference.

The poster presentation at this forum will be based the novel AI technology for TCR engineering from NEC Bio group and TG4050, highlighting median 24-month follow up from the ongoing randomized Phase I trial of its individualized therapeutic cancer vaccine, presented by Transgene. TG4050 asset is a collaboration between NEC and a French biotech, Transgene. The conference will be attended by delegates from NEC Bio group.

The abstract will be available on the SITC website on November 5, 2024.

Poster Details

Poster title: Design of Enhanced TCRs against Cancer Antigens Using and AI system. (Poster and abstract no. 1230)

• Authors: Martin Renqiang Min, Tianxiao Li, Kazuhide Onoguchi, Daiki Mori, Jonathan Warrell, Pierre Machart, Anja Moesch, Andrea Meiser, Ivy Grace Pait, Ayako Okamura, Daisuke Muraoka, Hirokazu Matsushita, Kaidre Bendjama
• Date: Thursday, 7th November 2024

Poster title: Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC). (Poster and abstract no. 650)

• Authors: C. Le Tourneau, JP Delord, A. Lalanne1, C. Jamet1, C. Spring-Giusti, A. Tavernaro, B. Bastien, M. Brandely, E. Quemeneur, K. Onoue, Y. Yamashita, N. Yamagata, K. Onoguchi, I. G. Pait, B. Malone, O. Baker, P. Brattas, O. Lantz, K. Bendjama, C. Ottensmeier
• Date: Thursday, 7th November 2024

About NEC Bio

NEC Bio, the biotech arm of NEC Corporation, is based in the Netherlands and dedicated to the development of innovative biotechnological solutions to tackle some of the most pressing health challenges. NEC Bio's research and development efforts are focused on creating personalized therapies that improve the quality of life for patients worldwide. NEC OncoImmunity in Oslo, Norway, is also a subsidiary of NEC Bio.

NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2024 NEC Corporation.